Protagonist Therapeutics, Inc. (PTGX) Balance Sheet

The sequential jump in total assets and cash from $193.7M to $420.1M in 2026Q2 aligns with the $213.5M revenue spike reported in the income statement, suggesting that milestone payments are being converted into cash reserves. However, the prior quarter's cash level of $193.7M was already elevated, indicating that the company is accumulating liquidity episodically. This pattern suggests that the balance sheet's strength is tied to non-recurring events rather than steady operational progress, warranting caution in extrapolating the trajectory.

The current ratio of 21.71 is exceptionally high, indicating that current assets vastly exceed current liabilities, which are minimal at $44.0M. Cash alone covers nearly ten times total liabilities, suggesting that the company has ample runway to fund R&D and SG&A expenses, which averaged around $50M per quarter in recent periods. However, the liquidity is heavily dependent on milestone timing; in quarters without milestones, cash levels have been lower (e.g., $97.2M in 2024Q4), so the current buffer may not be sustainable without future inflows.

The debt level has remained stable around $10M over the past year, likely representing a small lease or financing obligation, and is immaterial to the balance sheet. The D/E ratio of 0.01 is among the lowest in the peer set, even compared to Immunovant's 0.00, suggesting that PTGX is not reliant on debt to fund operations. This low leverage provides financial flexibility, but it also implies that the company is funding its operations primarily through equity and milestone cash, which may be a deliberate strategy to avoid fixed obligations given the lumpy revenue stream.

The improvement in retained earnings from -$466.9M to -$304.0M in 2026Q2 is directly attributable to the large net income reported in that quarter, which included a $28.6M stock-based compensation expense. While the equity base is strengthening, the retained earnings deficit remains substantial, indicating that cumulative losses still exceed cumulative profits. The company has not engaged in share repurchases or dividends, as noted in the cash flow analysis, so equity growth is purely from earnings and capital raises, which may dilute shareholders over time if additional financing is needed.

The sharp decline in PPE from $11.2M to $3.5M is unusual and may indicate a write-down or reclassification, but it is immaterial relative to total assets of $885.5M. The absence of goodwill and minimal PPE confirm that PTGX's value lies in its intangible pipeline assets, which are not capitalized on the balance sheet. This asset-light structure means that the balance sheet provides little collateral for debt, but it also reduces depreciation drag and allows for high gross margins, as seen in the income statement.